Quest Partners LLC Grows Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)

Quest Partners LLC raised its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 40,904.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 9,431 shares of the company’s stock after purchasing an additional 9,408 shares during the quarter. Quest Partners LLC’s holdings in Arcus Biosciences were worth $144,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Innealta Capital LLC bought a new stake in Arcus Biosciences during the second quarter valued at about $66,000. Point72 DIFC Ltd bought a new stake in shares of Arcus Biosciences during the second quarter valued at approximately $83,000. Diversified Trust Co lifted its stake in Arcus Biosciences by 12.1% in the 2nd quarter. Diversified Trust Co now owns 13,545 shares of the company’s stock worth $206,000 after purchasing an additional 1,467 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Arcus Biosciences in the second quarter worth about $254,000. Finally, ClariVest Asset Management LLC purchased a new stake in shares of Arcus Biosciences in the second quarter worth about $260,000. 92.89% of the stock is currently owned by institutional investors.

Arcus Biosciences Stock Performance

RCUS stock opened at $15.80 on Friday. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. The firm has a market cap of $1.45 billion, a price-to-earnings ratio of -5.02 and a beta of 0.89. The business’s fifty day simple moving average is $16.29 and its two-hundred day simple moving average is $16.05. Arcus Biosciences, Inc. has a twelve month low of $13.52 and a twelve month high of $20.31.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($1.00) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.06. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The company had revenue of $48.00 million for the quarter, compared to the consensus estimate of $38.95 million. During the same period last year, the business posted ($0.94) EPS. Arcus Biosciences’s quarterly revenue was up 50.0% on a year-over-year basis. Analysts predict that Arcus Biosciences, Inc. will post -3.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on RCUS shares. Evercore ISI raised Arcus Biosciences to a “strong-buy” rating in a research note on Friday, August 9th. Wells Fargo & Company started coverage on shares of Arcus Biosciences in a research note on Tuesday, October 8th. They issued an “overweight” rating and a $29.00 price objective for the company. Wedbush reissued an “outperform” rating and set a $36.00 price objective on shares of Arcus Biosciences in a research note on Thursday, November 7th. Barclays boosted their target price on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Friday, October 25th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arcus Biosciences in a research report on Thursday, October 3rd. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Arcus Biosciences presently has a consensus rating of “Buy” and an average target price of $34.00.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.